Details of Disease

General Information of Disease (ID: DISSN8XB)

• Disease Name: Soft tissue sarcoma
• Synonyms: malignant soft tissue tumour; malignant soft tissue tumor; non-Rhabdo. soft tissue sarcoma; connective tissue sarcoma; soft tissue sarcoma; malignant mesenchymal tumor; sarcoma of the soft tissue; soft part sarcoma; sarcoma of soft tissue; malignant mesenchymal tumour
• Disease Class: 2B57: Kaposi sarcoma
• Definition: A malignant neoplasm arising from muscle tissue, adipose tissue, blood vessels, fibrous tissue, or other supportive tissues excluding the bones.
• Disease Hierarchy:
  DISTC6NO: Malignant soft tissue neoplasm
  DISZDG3U: Sarcoma
  DISSN8XB: Soft tissue sarcoma
• ICD Code:
  ICD-11: ICD-11: 2B57
  ICD-9: ICD-9: 171
  Expand ICD-9: 171
• Disease Identifiers:
  MONDO ID: MONDO_0018078
  UMLS CUI: C4551687
  MedGen ID: 1642116
  HPO ID: HP:0030448
  Orphanet ID: 3394
  SNOMED CT ID: 424952003

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Olaratumab	DMNYOIX	Approved	Monoclonal antibody	[1]

This Disease is Treated as An Indication in 14 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Aldoxorubicin	DMHKCIS	Phase 3	NA	[2]
L19-TNF	DMPE9AE	Phase 3	Fusion protein	[3]
TRC105	DM1874J	Phase 3	Monoclonal antibody	[4]
8H9 I-131 mab	DMKADUF	Phase 2	Monoclonal antibody	[5]
Afamitresgene autoleucel	DM1GR4M	Phase 2	CAR-T cell therapy	[6]
Camsirubicin	DMEZLFT	Phase 2	Small molecular drug	[7]
CMB305	DMYYEM5	Phase 2	NA	[8]
GPX-150D	DMHNIGB	Phase 2	NA	[4]
Mecbotamab vedotin	DMU5KH4	Phase 2	Antibody drug conjugate	[9]
MNPR-201	DMTCSG9	Phase 2	NA	[2]
Ontuxizumab	DM0FJIE	Phase 2	Antibody	[4]
Palifosfamide	DMMIYZ7	Phase 2	Small molecular drug	[10]
TH-302	DMFU0JY	Phase 2	Small molecular drug	[11]
NC-6300	DM8WXJX	Phase 1	NA	[2]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 16 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
DEPDC1	TT8S9CM	Limited	Biomarker	[12]
ANTXR2	TTOD34I	moderate	Altered Expression	[13]
CSPG4	TT7MYXI	moderate	Biomarker	[14]
ENPP2	TTSCIM2	moderate	Altered Expression	[15]
RGS6	TTJ96M8	moderate	Genetic Variation	[16]
CD6	TTMF6KC	Strong	Biomarker	[17]
DHCR24	TTTK0NH	Strong	Biomarker	[18]
FGFR4	TT1KX2S	Strong	Genetic Variation	[19]
FUS	TTKGYZ9	Strong	Genetic Variation	[20]
HBEGF	TT15SL0	Strong	Genetic Variation	[21]
LATS2	TTML7FG	Strong	Genetic Variation	[22]
MAGEA3	TTWSKHD	Strong	Biomarker	[23]
MDM2	TT9TE0O	Strong	Genetic Variation	[24]
MTAP	TTDBX7N	Strong	Genetic Variation	[25]
PDGFRA	TT8FYO9	Strong	Biomarker	[26]
TACC3	TTQ4UFD	Strong	Altered Expression	[27]

This Disease Is Related to 44 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CCNB3	OT5V72D3	Limited	Biomarker	[28]
DEPDC1B	OTMVFOT1	Limited	Biomarker	[12]
PLAGL1	OTZAO900	Limited	Posttranslational Modification	[29]
ASPSCR1	OTXTOD10	moderate	Altered Expression	[30]
CAVIN2	OTFHHDRU	moderate	Biomarker	[31]
CD109	OTDADBM4	moderate	Altered Expression	[32]
CHAMP1	OTBGWU86	moderate	Genetic Variation	[33]
CIB2	OT9ZJX1I	moderate	Genetic Variation	[34]
CLEC11A	OT9KBH7C	moderate	Altered Expression	[35]
CORO7	OTG7MEAJ	moderate	Biomarker	[36]
CREB3L1	OT2JHIHM	moderate	Genetic Variation	[37]
CREB3L2	OT09MHV0	moderate	Genetic Variation	[37]
IMPACT	OTQ923OB	moderate	Biomarker	[38]
ING2	OT6H0EWF	moderate	Biomarker	[39]
KLLN	OTV3FPH0	moderate	Genetic Variation	[40]
MAPK8IP2	OTDUHLN0	moderate	Biomarker	[41]
MOV10L1	OTP978LK	moderate	Genetic Variation	[33]
MYCL	OT1MFQ5U	moderate	Genetic Variation	[42]
PIWIL2	OT1PXQIF	moderate	Biomarker	[43]
PRB2	OTAD4JZ0	moderate	Altered Expression	[44]
PRDM10	OTDDWU5Q	moderate	Genetic Variation	[45]
PRIMA1	OT9ITT3P	moderate	Biomarker	[46]
SMARCB1	OT2LP7LJ	moderate	Biomarker	[47]
SSX1	OTZ7NRCY	moderate	Genetic Variation	[48]
STK3	OTLNSCQD	moderate	Posttranslational Modification	[49]
TFE3	OTM99ZWH	moderate	Altered Expression	[30]
ANKRD36B	OT3MW415	Strong	Biomarker	[50]
ATF1	OT251CI0	Strong	Biomarker	[51]
BCOR	OTG013AX	Strong	Genetic Variation	[20]
BRINP1	OTEUVSCP	Strong	Altered Expression	[52]
CCAR2	OTLUDG5T	Strong	Biomarker	[52]
CD151	OTF3UZS7	Strong	Biomarker	[53]
CHSY1	OTB1XSSF	Strong	Altered Expression	[54]
CIC	OTFXCHNZ	Strong	Genetic Variation	[20]
EWSR1	OT7SRHV3	Strong	Biomarker	[20]
EXTL3	OT2BRUBN	Strong	Altered Expression	[54]
IRX2	OTBHXXQ2	Strong	Biomarker	[55]
NKD2	OTCYT3I6	Strong	Altered Expression	[55]
PPP2R5E	OT8GPFT5	Strong	Genetic Variation	[56]
S100A1	OT1F2G4J	Strong	Genetic Variation	[24]
SS18	OTDKHN1E	Strong	Biomarker	[57]
SSX2	OT2Z6RLL	Strong	Biomarker	[58]
STOM	OTC8R6EH	Strong	Biomarker	[59]
TBC1D9	OTSSCTB5	Strong	Altered Expression	[60]

References

• [1] 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] ClinicalTrials.gov (NCT04650984) A Phase III Study Comparing the Efficacy of the Combination of Doxorubicin and the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF to Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma. U.S.National Institutes of Health.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] ClinicalTrials.gov (NCT00582608) Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9. U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT04044768) A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR? T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma. U.S.National Institutes of Health.
• [7] Clinical pipeline report, company report or official report of Monopar Therapeutics.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Clinical pipeline report, company report or official report of BioAtla
• [10] ClinicalTrials.gov (NCT01808534) Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors. U.S. National Institutes of Health.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8695).
• [12] Prognostic role of XTP1/DEPDC1B and SDP35/DEPDC1A in high grade soft-tissue sarcomas.Histol Histopathol. 2018 Jun;33(6):597-608. doi: 10.14670/HH-11-959. Epub 2018 Jan 3.
• [13] CMG2 Expression Is an Independent Prognostic Factor for Soft Tissue Sarcoma Patients.Int J Mol Sci. 2017 Dec 7;18(12):2648. doi: 10.3390/ijms18122648.
• [14] Effects of chondroitin sulfate proteoglycan 4 (NG2/CSPG4) on soft-tissue sarcoma growth depend on tumor developmental stage.J Biol Chem. 2018 Feb 16;293(7):2466-2475. doi: 10.1074/jbc.M117.805051. Epub 2017 Dec 1.
• [15] c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas.J Pathol. 2014 Oct;234(2):190-202. doi: 10.1002/path.4379. Epub 2014 Aug 1.
• [16] Absence of mutation at the GAP-related domain of the neurofibromatosis type 1 gene in sporadic neurofibrosarcomas and other bone and soft tissue sarcomas.Cancer Genet Cytogenet. 1995 Jun;81(2):173-4. doi: 10.1016/0165-4608(94)00267-f.
• [17] No rearrangements of the CHOP gene in malignant fibrous histiocytoma.Cancer Genet Cytogenet. 1994 Feb;72(2):155-6. doi: 10.1016/0165-4608(94)90133-3.
• [18] Soft tissue sarcoma: DWI and DCE-MRI parameters correlate with Ki-67 labeling index.Eur Radiol. 2020 Feb;30(2):914-924. doi: 10.1007/s00330-019-06445-9. Epub 2019 Oct 18.
• [19] The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma.Exp Mol Pathol. 2007 Feb;82(1):53-7. doi: 10.1016/j.yexmp.2006.05.003. Epub 2006 Nov 3.
• [20] DNA methylation profiling distinguishes Ewing-like sarcoma with EWSR1-NFATc2 fusion from Ewing sarcoma.J Cancer Res Clin Oncol. 2019 May;145(5):1273-1281. doi: 10.1007/s00432-019-02895-2. Epub 2019 Mar 20.
• [21] First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours.Eur J Cancer. 2017 Nov;86:240-247. doi: 10.1016/j.ejca.2017.09.009. Epub 2017 Oct 19.
• [22] LATS tumor suppressor: a new governor of cellular homeostasis.Cell Cycle. 2010 Oct 1;9(19):3892-903. doi: 10.4161/cc.9.19.13386. Epub 2010 Oct 20.
• [23] MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma.Cancers (Basel). 2019 May 15;11(5):677. doi: 10.3390/cancers11050677.
• [24] GLI1-amplifications expand the spectrum of soft tissue neoplasms defined by GLI1 gene fusions.Mod Pathol. 2019 Nov;32(11):1617-1626. doi: 10.1038/s41379-019-0293-x. Epub 2019 Jun 12.
• [25] Identification of a novel MTAP-RAF1 fusion in a soft tissue sarcoma.Diagn Pathol. 2018 Oct 12;13(1):77. doi: 10.1186/s13000-018-0759-z.
• [26] Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model.Cancer Lett. 2019 Jun 1;451:122-127. doi: 10.1016/j.canlet.2019.03.003. Epub 2019 Mar 10.
• [27] Elevated Expression of Transforming Acidic Coiled-Coil Containing Protein 3 (TACC3) Is Associated With a Poor Prognosis in Osteosarcoma.Clin Orthop Relat Res. 2018 Sep;476(9):1848-1855. doi: 10.1097/CORR.0000000000000379.
• [28] BCOR-CCNB3-positive soft tissue sarcoma with round-cell and spindle-cell histology: a series of four cases highlighting the pitfall of mimicking poorly differentiated synovial sarcoma.Histopathology. 2016 Nov;69(5):792-801. doi: 10.1111/his.13001. Epub 2016 Jul 15.
• [29] Prognostic value of PLAGL1-specific CpG site methylation in soft-tissue sarcomas.PLoS One. 2013 Nov 15;8(11):e80741. doi: 10.1371/journal.pone.0080741. eCollection 2013.
• [30] Expression of MET in alveolar soft part sarcoma.Med Oncol. 2010 Jun;27(2):459-65. doi: 10.1007/s12032-009-9234-8. Epub 2009 May 27.
• [31] Cavin-2 is a specific marker for detection of well-differentiated liposarcoma.Biochem Biophys Res Commun. 2017 Nov 4;493(1):660-665. doi: 10.1016/j.bbrc.2017.08.135. Epub 2017 Sep 1.
• [32] High expression of CD109 antigen regulates the phenotype of cancer stem-like cells/cancer-initiating cells in the novel epithelioid sarcoma cell line ESX and is related to poor prognosis of soft tissue sarcoma.PLoS One. 2013 Dec 20;8(12):e84187. doi: 10.1371/journal.pone.0084187. eCollection 2013.
• [33] Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: a report of the CHAMP Study Group. Chromosomes and MorPhology.Genes Chromosomes Cancer. 1998 May;22(1):16-25. doi: 10.1002/(sici)1098-2264(199805)22:1<16::aid-gcc3>3.0.co;2-a.
• [34] Cyclin-dependent kinase inhibitor p57KIP2 in soft tissue sarcomas and Wilms'tumors.Cancer Res. 1996 Mar 15;56(6):1219-21.
• [35] Clinical Benefit of Pazopanib in a Patient with Metastatic Chondrosarcoma: A Case Report and Review of the Literature.Front Oncol. 2018 Mar 1;8:45. doi: 10.3389/fonc.2018.00045. eCollection 2018.
• [36] Postoperative Day 1 Glucose May Be Associated With Wound Complications in Sarcomas Treated With Preoperative Radiation.Clin Orthop Relat Res. 2018 Mar;476(3):580-586. doi: 10.1007/s11999.0000000000000056.
• [37] Low-grade fibromyxoid sarcoma with prominent giant rosettes and heterotopic ossification.Pathol Res Pract. 2012 Sep 15;208(9):557-60. doi: 10.1016/j.prp.2012.06.002. Epub 2012 Jul 20.
• [38] ROS1-GOPC/FIG: a novel gene fusion in hepatic angiosarcoma.Oncotarget. 2019 Jan 4;10(2):245-251. doi: 10.18632/oncotarget.26521. eCollection 2019 Jan 4.
• [39] Targeted disruption of Ing2 results in defective spermatogenesis and development of soft-tissue sarcomas.PLoS One. 2010 Nov 19;5(11):e15541. doi: 10.1371/journal.pone.0015541.
• [40] Alveolar rhabdomyosarcoma in an adolescent male patient - case report and current perspectives.Rom J Morphol Embryol. 2018;59(4):1247-1252.
• [41] Investigating a chimeric anti-mouse PDGFR antibody as a radiosensitizer in primary mouse sarcomas.EBioMedicine. 2019 Feb;40:224-230. doi: 10.1016/j.ebiom.2019.01.046. Epub 2019 Jan 31.
• [42] Elevated frequency of a specific allele of the L-myc gene in male patients with bone and soft-tissue sarcomas.Int J Cancer. 1990 Jan 15;45(1):47-9. doi: 10.1002/ijc.2910450110.
• [43] Expression of human Piwi-like genes is associated with prognosis for soft tissue sarcoma patients.BMC Cancer. 2012 Jun 29;12:272. doi: 10.1186/1471-2407-12-272.
• [44] The retinoblastoma family member pRb2/p130 is an independent predictor of survival in human soft tissue sarcomas.Clin Cancer Res. 2008 Aug 1;14(15):4775-9. doi: 10.1158/1078-0432.CCR-07-4055.
• [45] Recurrent PRDM10 gene fusions in undifferentiated pleomorphic sarcoma.Clin Cancer Res. 2015 Feb 15;21(4):864-9. doi: 10.1158/1078-0432.CCR-14-2399. Epub 2014 Dec 16.
• [46] PRIMA-1(MET) induces death in soft-tissue sarcomas cell independent of p53.BMC Cancer. 2015 Oct 13;15:684. doi: 10.1186/s12885-015-1667-1.
• [47] The oncomir face of microRNA-206: A permanent miR-206 transfection study.Exp Biol Med (Maywood). 2018 Aug;243(12):1014-1023. doi: 10.1177/1535370218795406. Epub 2018 Aug 15.
• [48] Real-time polymerase chain reaction as an aid for the detection of SYT-SSX1 and SYT-SSX2 transcripts in fresh and archival pediatric synovial sarcoma specimens: report of 25 cases from St. Jude Children's Research Hospital.Pediatr Dev Pathol. 2003 Jan-Feb;6(1):24-34. doi: 10.1007/s10024-002-0050-9. Epub 2002 Dec 10.
• [49] Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma.Mol Carcinog. 2007 Oct;46(10):865-71. doi: 10.1002/mc.20317.
• [50] Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY-ESO-1 and MAGE-A4 in high-grade soft-tissue sarcoma.Oncol Lett. 2019 Apr;17(4):3937-3943. doi: 10.3892/ol.2019.10044. Epub 2019 Feb 14.
• [51] Fusion of the EWSR1 and ATF1 genes without expression of the MITF-M transcript in angiomatoid fibrous histiocytoma.Genes Chromosomes Cancer. 2005 Sep;44(1):97-102. doi: 10.1002/gcc.20201.
• [52] Expression of SIRT1 and DBC1 is associated with poor prognosis of soft tissue sarcomas.PLoS One. 2013 Sep 3;8(9):e74738. doi: 10.1371/journal.pone.0074738. eCollection 2013.
• [53] CD151 confers metastatic potential to clear cell sarcoma of the soft tissue in animal model.Oncol Lett. 2019 Jun;17(6):4811-4818. doi: 10.3892/ol.2019.10164. Epub 2019 Mar 19.
• [54] Chondroitin sulfate synthase 1 expression is associated with malignant potential of soft tissue sarcomas with myxoid substance.Hum Pathol. 2016 Apr;50:15-23. doi: 10.1016/j.humpath.2015.11.005. Epub 2015 Nov 22.
• [55] Frequent amplifications and abundant expression of TRIO, NKD2, and IRX2 in soft tissue sarcomas.Genes Chromosomes Cancer. 2006 Sep;45(9):829-38. doi: 10.1002/gcc.20343.
• [56] PP2A:B56{epsilon}, a substrate of caspase-3, regulates p53-dependent and p53-independent apoptosis during development.J Biol Chem. 2010 Nov 5;285(45):34493-502. doi: 10.1074/jbc.M110.169581. Epub 2010 Aug 31.
• [57] The prognostic impact of SYT-SSX fusion type and histological grade in pediatric patients with synovial sarcoma treated according to the CWS (Cooperative Weichteilsarkom Studie) trials.Pediatr Blood Cancer. 2017 Jan;64(1):89-95. doi: 10.1002/pbc.26206. Epub 2016 Sep 13.
• [58] A novel sarcoma with dual differentiation: clinicopathologic and molecular characterization of a combined synovial sarcoma and extraskeletal myxoid chondrosarcoma.Am J Surg Pathol. 2012 Jul;36(7):1093-8. doi: 10.1097/PAS.0b013e31824cd174.
• [59] Simultaneous expression of flotillin-1, flotillin-2, stomatin and caveolin-1 in non-small cell lung cancer and soft tissue sarcomas.BMC Cancer. 2014 Feb 17;14:100. doi: 10.1186/1471-2407-14-100.
• [60] MDR1 gene expression: evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas.Eur J Cancer. 1996 Jan;32A(1):86-92. doi: 10.1016/0959-8049(95)00478-5.